Methods and compositions for treating excessive sleepiness
AssigneeAxsome Malta Ltd.
InventorsLawrence Patrick CARTER, Yuan Lu, Katayoun Zomorodi
Life of this patent
Estimating the term…
Abstract
The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders. The invention further relates to the development of methods for treating excessive sleepiness in a subject, e.g., due to narcolepsy or obstructive sleep apnea, with the surprising outcome that “normal” levels of wakefulness are achieved based on standard objective and subjective sleepiness tests.
Claims20
A method for treating excessive daytime sleepiness in a subject in need thereof, comprising administering once daily to the subject a pharmaceutical composition comprising (R)-2-amino-3-phenylpropyl carbamate (APC) or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition is administered to the subject within 3 hours of the subject waking, and wherein the pharmaceutical composition is an immediate release compressed tablet, the tablet comprising:
- APC or a pharmaceutically acceptable salt thereof in an amount of about 90-98% by weight of the tablet;
- at least one binder in an amount of about 1-5% by weight of the tablet;
- and
- at least one lubricant in an amount of about 0.1-2% by weight of the tablet;
- wherein the tablet releases at least 85% of APC or a pharmaceutically acceptable salt thereof contained therein within a period of less than 15 minutes after administration of the tablet to the subject.
A method for minimizing insomnia while treating excessive daytime sleepiness in a subject in need thereof, comprising administering once daily to the subject a pharmaceutical composition comprising (R)-2-amino-3-phenylpropyl carbamate (APC) or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition is administered to the subject within 3 hours of the subject waking, and wherein the pharmaceutical composition is an immediate release compressed tablet, the tablet comprising:
- APC or a pharmaceutically acceptable salt thereof in an amount of about 90-98% by weight of the tablet;
- at least one binder in an amount of about 1-5% by weight of the tablet;
- and
- at least one lubricant in an amount of about 0.1-2% by weight of the tablet;
- wherein the tablet releases at least 85% of APC or a pharmaceutically acceptable salt thereof contained therein within a period of less than 15 minutes after administration of the tablet to the subject.
Dependencies are inferred from the claim text.